Huaxia Shengsheng Pharmaceutical (Beijing) Co., Ltd.

Primary objective: This study is a bioequivalence study, with hydroxyethyl starch 130/0.4 sodium chloride injection (trade name: Voluven 6%, specification: 500ml) produced by Fresenius Kabi Deutschland GmbH as the reference preparation, and hydroxyethyl starch 130/0.4 sodium chloride injection (specification: 500ml: 30g hydroxyethyl starch 130/0.4 and 4.5g sodium chloride) produced by Huaxia Shengsheng Pharmaceutical (Beijing) Co., Ltd. as the test preparation. This clinical trial is designed as a single-center, randomized, open, two-preparation, two-period, double-crossover, and single-dose after meal, to evaluate the bioequivalence of the two preparations under the condition of postprandial administration. Secondary objective: To evaluate the safety of the test preparation and reference preparation after a single postprandial administration in healthy Chinese subjects.

Primary objective: To observe the pharmacokinetic characteristics of a single subcutaneous injection of the test preparation progesterone injection and the reference preparation (trade name: Lubion) in healthy Chinese postmenopausal women, and to evaluate the bioequivalence and intra-individual variability between the two preparations of a single subcutaneous injection of progesterone injection. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy Chinese postmenopausal women.

A pharmacokinetic study of roflumilast tablets (test preparation) was conducted on healthy volunteers after single and multiple oral administration of three doses and the effect of food, to explore the pharmacokinetic changes of the test drug's absorption, distribution and elimination in the human body and provide a reference for clinical application.